When comparing the DLX6-AS1 methylation levels between different stages of colorectal lesions (Table 2), the DLX6-AS1 promoter was revealed to be significantly hypermethylated between CRC vs. NAA (P < 0.001) and AA vs. NAA (P = 0.004) but not between CRC vs. AA (P = 1.000). Here, DLX6 is linked to colorectal carcinoma.